Related Experiment Video

Updated: Sep 21, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Antiandrogenic therapy for the treatment of early stage prostatic cancer

R Nishimura, K Shida

    The Prostate. Supplement
    |January 1, 1981
    PubMed

    Insights

    Chlormadinone acetate (CMA) shows significant antitumor effects in early-stage prostate cancer. This antiandrogen is recommended as a first-choice treatment due to its efficacy and safety profile in clinical trials.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Prostate cancer treatment often involves managing hormone-dependent tumor growth.
    • Antiandrogens are a key therapeutic class for advanced prostate cancer.

    Purpose of the Study:

    • To evaluate the clinical efficacy and safety of chlormadinone acetate (CMA) for treating prostate cancer.
    • To determine the optimal stage for CMA application in prostate cancer therapy.

    Main Methods:

    • A nationwide clinical trial involving nine universities and affiliated hospitals.
    • Administration of chlormadinone acetate (CMA) at 100 mg daily for up to 6.3 years.
    • Assessment of therapeutic effects across different stages (A, B, C, D) of prostate cancer.

    Main Results:

    • Highly satisfactory antitumor effects observed in stages A and B prostate cancer patients.
    • Good antitumor effects noted in stage C prostate cancer patients.
    • Limited efficacy reported for stage D prostate cancer patients.

    Conclusions:

    • Chlormadinone acetate (CMA) demonstrates significant efficacy in early to mid-stage prostate cancer.
    • CMA is well-tolerated, with no serious side effects reported despite long-term use and high dosage.
    • CMA is recommended as a first-choice drug for prostate cancer treatment, particularly in earlier stages.

    More Related Videos

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...